RxDoctor Payments Data

Benjamin Kilpatrick, MD

Cardiovascular Disease · Baton Rouge, LANPI 1326572074

Payments from drug & device makers

$1,526in general payments, 2019–2025

Across 55 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$279
  • Boston Scientific$195
  • Abbott$141
  • Novo Nordisk$124
  • Medtronic$121
  • Lantheus Medical Imaging, Inc.$100
  • plus $566 from 14 others

What the payments were for

  • Food & beverage$1,35489%
  • Education$17211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,526 in reported general payments places this provider in the 35th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$183,862
Medicare patients
429
Services billed
1,683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban300$241,118
XareltoRivaroxaban31$31,851
Acebutolol Hcl582$29,157
FarxigaDapagliflozin Propanediol24$18,710
MounjaroTirzepatide13$13,522
EntrestoSacubitril/Valsartan13$10,159
Ranolazine ErRanolazine94$8,268
NexlizetBempedoic Acid/Ezetimibe11$7,799
Metoprolol Succinate315$3,493
Rosuvastatin Calcium225$2,791
Atorvastatin Calcium316$2,746
ClopidogrelClopidogrel Bisulfate291$2,731
Isosorbide Mononitrate ErIsosorbide Mononitrate208$2,597
Losartan Potassium211$2,095
Nifedipine ErNifedipine136$1,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$241,118300 claims
Lilly USA, LLCMounjaro$17$13,52213 claims
NovartisEntresto$71$10,15913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →